Here are four things to know:
1. SI-BONE booked $52 million in revenue for the 12 months ending June 30.
2. Morgan Stanley and Bank of America Merrill Lynch are the deal’s joint bookrunners.
3. Pricing terms were not disclosed.
4. SI-BONE develops the iFuse Implant System, a minimally invasive sacroiliac joint disorder treatment.
More articles on devices:
NuVasive welcomes CEO of Google, Johnson & Johnson partnership company to board
Medtronic adds to spine business with $1.64B acquisition of Mazor: 6 things to know
SpineEx files for $17M IPO: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
